Association of sarcopenia with atrial fibrillation: protocol for a systematic review and meta-analysis Authors: Peng Wang, Wentao Shi, Guojie Ye Published: 2025 ABSTRACT BackgroundSarcopenia is a clinical syndrome characterized by a significant reduction in muscle mass and strength, typically associated with the ageing process. In recent years, an increasing number of studies have shown that sarcopenia not only affects functional health in the elderly but may also be closely associated with the onset of cardiovascular diseases, particularly atrial fibrillation. However, the association between sarcopenia and atrial fibrillation has not yet been adequately systematically evaluated. Therefore, this study aims to investigate the relationship between sarcopenia and atrial fibrillation through a systematic review and meta-analysis.MethodsThe study will adhere to the PRISMA-P guidelines to ensure a transparent and rigorous methodology and will conduct a comprehensive literature search using databases PubMed, Embase, the Cochrane Library, and Web of Science, with the search period spanning from the establishment of the databases to 15 May 2025. Included will be clinical observational studies that meet the criteria, including prospective cohort studies, and case–control studies. The included studies must explicitly assess the association between sarcopenia and the occurrence of atrial fibrillation. We will assess the risk of bias of all included studies using the Newcastle–Ottawa Scale (NOS) and the AHRQ quality assessment tool. The data for this study will be analyzed using Stata 15. We will employ random-effects models for statistical analysis, along with subgroup analysis, to further explore the potential influence of factors such as age, gender, and disease status on the results.DiscussionThe primary objective of this study is to assess the impact of sarcopenia on atrial fibrillation and to analyze their potential association. This study is expected to reveal the potential association between sarcopenia and atrial fibrillation and provide evidence-based support for clinical prevention and treatment. The study results will help promote early identification and intervention for sarcopenia, thereby reducing the risk of atrial fibrillation and improving health outcomes for the elderly population.Systematic review registrationProspero CRD420251054023.Supplementary InformationThe online version contains supplementary material available at 10.1186/s13643-025-03015-7. Background Sarcopenia is a condition characterized by a gradual decline in skeletal muscle mass, strength, and function as people age, often accompanied by a decline in overall physical function and limitations in activities of daily living [1, 2]. In recent years, with the arrival of an ageing society, sarcopenia has become a significant global health issue. Sarcopenia not only affects the quality of life of the elderly but is also closely associated with various chronic diseases (cardiovascular disease, diabetes, osteoporosis) and is significantly linked to increased mortality rates, hospitalization rates, and dependence on healthcare [3]. The pathogenesis of sarcopenia is complex, involving multiple factors such as chronic low-grade inflammation, endocrine disorders, malnutrition, and neuromuscular dysfunction [4]. Chronic inflammation is considered one of the key pathophysiological mechanisms of sarcopenia, with increased levels of inflammatory factors in the body potentially promoting muscle degeneration [5]. The diagnosis of sarcopenia is typically based on reduced muscle mass, decreased muscle strength, and impaired physical function, a process that is age-related and progressive [6]. Atrial fibrillation refers to abnormalities in heart rhythm [7]. The occurrence of atrial fibrillation is closely related to various factors, particularly structural heart lesions, electrophysiological abnormalities, and dysregulation of the nervous system [8]. The clinical manifestations of atrial fibrillation are diverse; mild cases may only present with symptoms such as palpitations, while severe cases may lead to life-threatening complications such as heart failure or stroke [9]. With the aging of the population, the incidence of atrial fibrillation has been increasing annually, making it one of the most common cardiovascular diseases in the elderly population [10]. Recent studies [11, 12] have shown that sarcopenia may be associated with the occurrence of atrial fibrillation through multiple mechanisms. First, sarcopenia is often accompanied by chronic low-grade systemic inflammation. Studies [13] have shown that inflammatory markers such as C-reactive protein (CRP) and interleukin-6 (IL-6) are commonly elevated in patients with sarcopenia, and these inflammatory markers are closely related to the regulation of cardiac electrophysiology. Chronic inflammation may alter cardiac electrical activity, thereby triggering atrial fibrillation. Second, sarcopenia is closely related to autonomic nervous system dysfunction. Sarcopenia patients often exhibit increased sympathetic nervous activity and weakened vagus nerve function. This imbalance in the nervous system exacerbates cardiac electrophysiological instability, thereby increasing the risk of atrial fibrillation [14]. Sarcopenia patients, due to reduced mobility, often have poor exercise tolerance and reduced physical activity, which further exacerbates autonomic nervous system dysfunction. Additionally, patients with sarcopenia often suffer from malnutrition, particularly deficiencies in protein and trace elements [15]. Electrolyte imbalances, especially imbalances in potassium, calcium, and magnesium ions, are known risk factors for atrial fibrillation. Although some studies [16, 17] have explored the association between sarcopenia and atrial fibrillation, most existing studies are cross-sectional in design and have small sample sizes, which limits the generalizability and reliability of their conclusions. Differences in study results may stem from varying research methods, clinical characteristics, and confounding factors. Additionally, the relationship between sarcopenia and different types of atrial fibrillation has not been sufficiently studied, and existing studies often fail to adequately control for potential confounding factors. Whether different types of atrial fibrillation have different associations with sarcopenia also requires further exploration and comparison [18]. Therefore, conducting a systematic review and meta-analysis to summaries and analyze existing literature can provide more reliable evidence to clarify the relationship between sarcopenia and atrial fibrillation. This study will focus on assessing whether sarcopenia may be associated with atrial fibrillation and exploring possible mechanisms. Through systematic analysis and comparison, this study aims to provide a theoretical basis for the prevention atrial fibrillation in patients with sarcopenia in clinical practice, while also contributing to the improvement of early diagnosis and comprehensive treatment strategies for sarcopenia. Methods Protocol and registration The program will construct in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocol (PRISMA-P) guidelines [19] (Supplementary Material 1). This study will be scheduled to begin on May 15, 2025, and end on December 30, 2025. This study was pre-registered with the International prospective register of systematic reviews (PROSPERO) under the registration number (Supplementary Material 2): CRD420251054023. Inclusion criteria Eligible participants are adults (≥ 18 years) with sarcopenia defined by widely accepted criteria (EWGSOP2, AWGS, or FNIH). Given regional differences in diagnostic thresholds (Asian versus European cut-offs for muscle mass), subgroup analyses will be performed based on diagnostic criteria. Atrial fibrillation must be diagnosed by objective measures (standard 12-lead ECG, Holter monitoring, or physician-confirmed medical records). To ensure temporal validity, studies assessing sarcopenia status before or at the same time as AF diagnosis will be considered. Additionally, the included literature must be publicly published and peer-reviewed studies, with no language restrictions for this study. Exclusion criteria Exclusion criteria include studies lacking a control group, studies with methodological flaws, or studies that are solely case reports or review articles. Additionally, studies focusing on intervention effects (pharmacological or physical therapy) rather than natural associations will be excluded, as will studies evaluating sarcopenia status after AF diagnosis. These standards facilitate the systematic evaluation of the relationship between sarcopenia and atrial fibrillation through subsequent meta-analyses. Literature retrieval Literature searches will be conducted in multiple core databases, including PubMed, Embase, Web of Science, and the Cochrane Library. Search strategies will utilize keywords related to ‘sarcopenia’ and ‘atrial fibrillation,’ combined with Boolean logic operators (AND, OR) for precise retrieval. The time scope of the literature search is limited to the period from the establishment of the databases to 15 May 2025 to ensure the timeliness of the literature. The specific search strategy is detailed in Supplementary Material 3. Data collection and analysis Study collection Two authors must independently screen the retrieved studies, excluding duplicates (Endnote21) and those that do not meet inclusion criteria by reading titles and abstracts. They will review the full text of each study to select those that qualify. Any disagreements will be resolved through discussion with a third reviewer. Data extraction Data extraction from the included studies will be carried out independently by two reviewers using a predefined data acquisition list. This list will capture basic information (author, title, journal, year and country of publication), study design (including study size), and any conflicts of interest. If necessary, a third reviewer will double-check the data for consistency. If data is missing or incomplete, we will contact the study authors to obtain it. Studies without available data (such as hazard ratios (HR), odds ratios (OR), or relative risks (RR) along with their 95% confidence intervals) will be included in the narrative synthesis. Assessment of risk of bias The risk of bias in the included studies will be evaluated independently by two investigators, and the results will be cross-checked. For cohort and case–control studies, the Newcastle Ottawa Scale (NOS [20]) will be used to assess quality. The NOS evaluates studies based on three dimensions: population selection, comparability, and exposure or outcome, with eight items totaling nine points. Scores range from 0 to 4 (low quality), 5 to 6 (moderate quality), and 7 to 9 (high quality). Studies scoring 0 to 4 will be excluded. For cross-sectional studies, this study will use the AHRQ quality [21] assessment tool will be applied, given the prevalence of such designs in sarcopenia research. This tool primarily assesses the rationality of the study design, the representativeness of the sample selection, the clarity of the definitions of exposure and outcome, the accuracy of the data collection process, the rationality of the statistical methods, and the completeness of the report. Measures of association Stata 15.0 will be used for statistical analysis, sensitivity evaluation, and publication bias assessment. The association between sarcopenia and atrial fibrillation will be summarized using pooled odds ratios (ORs) with 95% confidence intervals (CIs) under a random-effects model. Odds ratios (ORs) are the most reported effect measure across studies and provide a mathematically stable and comparable metric for synthesizing data across different study designs. While ORs can sometimes overestimate the association for common outcomes if misinterpreted as risk ratios, they remain an appropriate measure in this context and will be used consistently in the primary analysis. In contrast, risk ratios (RRs) or prevalence ratios (PRs) will be analyzed separately in a sensitivity analysis to evaluate the robustness of the findings. No conversions between ORs and RRs will be performed in the primary analysis to avoid potential bias. All effect estimates will be transformed to the log scale for pooling and subsequently back transformed for presentation. In addition to dichotomous outcomes, we will include studies reporting sarcopenia or atrial fibrillation (AF) as continuous variables. For sarcopenia measured as a continuous outcome (appendicular skeletal muscle mass index [ASMI, kg/m2]), we will extract mean differences or standardized mean differences (SMDs). When validated diagnostic cut-off points are available (e.g., ASMI < 7.0 kg/m2 for men and < 5.7 kg/m2 for women, as recommended by the Asian Working Group for Sarcopenia 2019), we will convert continuous measures into binary classifications (“with sarcopenia” vs. “without sarcopenia”) to align with the primary dichotomous analysis. If such validated cut-offs are unavailable or vary across studies, the data will remain in continuous form and will be analyzed separately using random-effects meta-analysis of SMDs. For atrial fibrillation outcomes reported continuously (AF burden, AF duration), we will extract mean differences or SMDs and synthesize them separately. If the number of available studies is insufficient for quantitative synthesis (fewer than three studies), we will provide a structured narrative synthesis instead of meta-analysis. This pre-specified plan minimizes post-hoc analytical decisions and ensures consistency in data handling. Assessment of heterogeneity Heterogeneity will be assessed using Cochrane's Q test and the I2 statistic. A p-value < 0.1 for the Q test and I2 < 50% will indicate statistical homogeneity. Given the expected heterogeneity across studies, a random-effects model will be used for all meta-analyses. While I2 values above 75% suggest high heterogeneity, we will proceed with a random-effects model for all meta-analyses, as this model accounts for between-study variability. In the case of significant heterogeneity, subgroup analyses will be conducted to explore potential sources of variability based on factors such as study design, participant characteristics, and diagnostic criteria. This approach will allow us to better understand the sources of heterogeneity and refine the interpretation of the results. The between-study variance (τ2) will be estimated primarily using the restricted maximum likelihood (REML) method, which is preferred in modern meta-analysis practice, especially when there are a small number of studies. The REML method provides a more accurate estimate of between-study variance compared to the DerSimonian and Laird (DL) method, particularly in cases with limited studies. These methods will be used to assess the variability between studies, and the I2 statistic will be used to quantify the proportion of total variation across studies due to heterogeneity rather than chance. Quality of evidence The certainty of evidence will be evaluated using the GRADE approach. Observational studies start at moderate certainty but may be downgraded for risk of bias, inconsistency, indirectness, imprecision, or publication bias. Certainty may also be upgraded if large effect sizes or dose–response relationships are evident. Assessment of publication biases Publication bias and small-study effects will be assessed using multiple complementary methods. When ≥ 10 studies are available for an outcome, funnel plot asymmetry will be visually inspected to assess potential publication bias. In addition, statistical tests, including Egger’s regression test and Harbord’s test, will be applied to detect small-study effects. To further assess and adjust for potential publication bias or small-study effects, the trim-and-fill method will be employed. This method imputes missing studies based on the observed asymmetry in the funnel plot, thereby estimating the potential impact of unpublished or missing studies on the pooled effect size. The trim-and-fill approach works by removing (trimming) studies from the funnel plot to make it symmetric, then adding (filling) studies to adjust the effect size estimate. Sensitivity analyses will be conducted to assess the robustness of the results, including excluding small studies or those with extreme effect sizes. Should publication bias or small-study effects be detected, their potential impact will be explicitly discussed in the final review. Subgroup analysis To account for variability in sarcopenia definitions, we will apply a hierarchical subgrouping strategy. First, studies will be categorized based on the core diagnostic components:Muscle mass only (e.g., low appendicular muscle mass by DXA or BIA).Muscle mass + muscle strength (EWGSOP2, AWGS).Muscle mass + muscle strength + physical function (e.g., gait speed, chair stand test).Within each category, subgroup analyses will also be performed according to the specific diagnostic consensus used (EWGSOP, EWGSOP2, AWGS, FNIH, AGS). This pre-specified hierarchical approach will allow us to systematically explore how differences in sarcopenia definitions influence the observed association with atrial fibrillation, and to reduce bias arising from post hoc grouping. Muscle mass only (e.g., low appendicular muscle mass by DXA or BIA). Muscle mass only (e.g., low appendicular muscle mass by DXA or BIA). Muscle mass + muscle strength (EWGSOP2, AWGS). Muscle mass + muscle strength (EWGSOP2, AWGS). Muscle mass + muscle strength + physical function (e.g., gait speed, chair stand test). Muscle mass + muscle strength + physical function (e.g., gait speed, chair stand test). Within each category, subgroup analyses will also be performed according to the specific diagnostic consensus used (EWGSOP, EWGSOP2, AWGS, FNIH, AGS). This pre-specified hierarchical approach will allow us to systematically explore how differences in sarcopenia definitions influence the observed association with atrial fibrillation, and to reduce bias arising from post hoc grouping. Within each category, subgroup analyses will also be performed according to the specific diagnostic consensus used (EWGSOP, EWGSOP2, AWGS, FNIH, AGS). This pre-specified hierarchical approach will allow us to systematically explore how differences in sarcopenia definitions influence the observed association with atrial fibrillation, and to reduce bias arising from post hoc grouping. Sensitivity analysis When both adjusted and unadjusted estimates are reported, we will prioritize adjusted effect sizes. A minimal set of key confounders (age, sex, body mass index, diabetes, hypertension, and heart failure) has been pre-specified based on their well-established associations with both sarcopenia and atrial fibrillation. The primary analysis will include all studies that report any adjusted estimates, regardless of whether all six confounders were included, to maximize data utilization while acknowledging potential residual confounding. The secondary analysis will be restricted to studies that adjust for the full minimal confounder set, providing a high-quality adjusted estimate. Additionally, we will explore whether the number or type of adjusted confounders modifies the pooled association using meta-regression analyses. However, due to the typically small number of studies in meta-analysis (10–20 studies), the statistical power of these meta-regressions may be limited. As such, the results of meta-regression analyses should be interpreted with caution and treated as exploratory rather than conclusive. This tiered approach allows us to balance inclusivity and methodological rigor, minimizing the risk of excluding valuable data and enabling comprehensive sensitivity assessment. Ethics and dissemination This review does not require ethical approval as it does not infringe on individual rights. Results will be published in a peer-reviewed journal and disseminated through conferences. Discussion This study aims to investigate the association between sarcopenia and atrial fibrillation through systematic review and meta-analysis. Previous studies have shown that sarcopenia is associated with various conditions such as cardiovascular disease and metabolic syndrome; however, the relationship between sarcopenia and atrial fibrillation has not been fully explored. By compiling existing literature, this study aims to reveal the potential relationship between the two and provide a theoretical basis for future research. The association between sarcopenia and cardiovascular health has been confirmed in multiple studies, with previous research indicating that CVD is associated with impaired physical function [22]. Building on this background, we found that among the components of sarcopenia, impaired physical function may be associated with atrial fibrillation. In previous studies, compared with the control group, ATRIAL FIBRILLATION patients had a reduced skeletal muscle mass ratio, but increased body mass index, fat mass, and waist circumference [23]. Xia et al. [24] found that concomitant low muscle mass and obesity/overweight (rather than low muscle mass alone) were significantly associated with an increased risk of atrial fibrillation. Mechanistically, sarcopenia and obesity may have effect on atrial fibrillation. Sarcopenia is believed to lead to cardiac dysfunction, mediated by impaired cardiopulmonary function and reduced physical performance [25]. Another mechanism is that subclinical CVD may negatively impact left ventricular filling and cardiac output, thereby reducing physical performance [26]. atrial fibrillation can cause several discomforting symptoms, such as palpitations, dyspnea, and fatigue, which may lead to reduced activity capacity and subsequent frailty. Increasing evidence suggests an association between atrial fibrillation and frailty in the elderly. Notably, atrial fibrillation may contribute to the development of the sarcopenia phenotype [27]. However, existing studies [28, 29] exhibit significant inconsistencies in elucidating the relationship between sarcopenia and atrial fibrillation. Different studies employ varying diagnostic criteria for sarcopenia, such as assessments based on muscle mass or muscle strength, while others define sarcopenia through measurements of muscle function. These differences may lead to heterogeneity in research results, making it difficult to draw consistent conclusions across all studies. Strengths This study will integrate existing research data through a systematic review and meta-analysis, revealing a potential association between sarcopenia and atrial fibrillation, thereby providing comprehensive evidence for scientific research in this field. Clinical significance If a strong association between sarcopenia and atrial fibrillation is found, this would highlight the need for future longitudinal studies to explore potential causal mechanisms. It would also provide a foundation for subsequent interventional trials to assess whether preventing or treating sarcopenia could reduce the risk of atrial fibrillation. However, the results of this meta-analysis are intended to generate hypotheses and inform future research rather than provide immediate clinical recommendations or directly influence clinical guidelines. Supplementary Information Supplementary Material 1.Supplementary Material 2.Supplementary Material 3. Supplementary Material 1. Supplementary Material 2. Supplementary Material 3.